动物实验,慢性睡眠干扰 z-bo 2020-08-28 433

　　Objective: To study the antidepressant effect of ginsenoside hydrolysate DS-1226 on mice with chronic sleep disorders and provide scientific basis for the development of antidepressant drugs.

　　Methods: 72 male ICR mice, empty control group, model group, positive control group (paroxetine hydrochloride 10 mg/kg), DS-1226 low-dose group (20 mg/kg), middle-dose group (40 mg/kg) )), high-dose group (80 mg/kg). Except for the blank group, the mice in the other groups first adapted to the roller for 3 days, and then interrupted for 14 days. The antidepressant effect of DS-1226 was evaluated using experimental methods such as weight monitoring, autonomous activity experiment, tail suspension experiment and forced swimming experiment.

　　Results: Compared with the empty control group, after 14 consecutive days of sleep disturbance, the model group lost a lot of weight and had more time to lower its tail or forced swimming. Compared with the model group, the DS-1226 medium-dose group It can significantly reverse the weight loss caused by sleep disorders, while other dose groups cannot significantly reverse the weight loss caused by sleep disorders. The tail suspension time of the positive drug group was significantly reduced, and significantly decreased, and the immobility time of forced swimming tended to decrease; the tail retention time of the DS-1226 dose was significantly reduced. The fixed time tends to be significantly reduced; the DS-1226 high-dose group has both tail stop and forced swimming fixed time, which is greatly reduced.

　　Conclusion: DS-1226 can effectively improve depression-like behavior in mice with chronic sleep disorders.